
Short Bowel Syndrome - Pipeline Insight, 2025
Description
DelveInsight’s, “Short Bowel Syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Short Bowel Syndrome: Overview
Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome). Although these congenital cases are often associated with malrotation of the small intestine, the exact cause of congenital short bowel syndrome is unknown. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or with part of their bowel missing, which can cause short bowel syndrome. In infants, short bowel syndrome most commonly occurs following surgery to treat necrotizing enterocolitis, a condition in which part of the tissue in the intestines is destroyed
""Short Bowel Syndrome- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided which includes the disease overview and Short Bowel Syndrome treatment guidelines. The assessment part of the report embraces, in depth Short Bowel Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Short Bowel Syndrome Emerging Drugs
Further product details are provided in the report……..
Short Bowel Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Short Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Short Bowel Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Short Bowel Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Short Bowel Syndrome drugs.
Short Bowel Syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Short Bowel Syndrome: Overview
Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome). Although these congenital cases are often associated with malrotation of the small intestine, the exact cause of congenital short bowel syndrome is unknown. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or with part of their bowel missing, which can cause short bowel syndrome. In infants, short bowel syndrome most commonly occurs following surgery to treat necrotizing enterocolitis, a condition in which part of the tissue in the intestines is destroyed
""Short Bowel Syndrome- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided which includes the disease overview and Short Bowel Syndrome treatment guidelines. The assessment part of the report embraces, in depth Short Bowel Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Short Bowel Syndrome.
- In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).
Short Bowel Syndrome Emerging Drugs
- Glepaglutide: Zealand Pharma
Further product details are provided in the report……..
Short Bowel Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Short Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Short Bowel Syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Molecule Type
- Peptide
- Protein
- Propylene glycols
- Cell Therapy
- Product Type
Short Bowel Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Short Bowel Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Short Bowel Syndrome drugs.
Short Bowel Syndrome Report Insights
- Short Bowel Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Short Bowel Syndrome drugs?
- How many Short Bowel Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Short Bowel Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Short Bowel Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Short Bowel Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- VectivBio
- Zealand Pharma
- 9 Meters Biopharma
- Hanmi Pharmaceutical
- Adocia
- PhaseBio Pharmaceuticals
- Surrozen
- NorthSea Therapeutics
- Benralizumab
- Apraglutide
- Glepaglutide
- Vurolenatide
- HM15912
- NM-002
- BioChaperone GLP-2
- GLP2-ELP
- Research programme: regenerative therapeutics
- SEFA-6179
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Short Bowel Syndrome: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Short Bowel Syndrome – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Glepaglutide: Zealand Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HM 15912: Hanmi Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Vurolenatide: 9 Meters Biopharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SEFA-6179: NorthSea Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- GLP2-ELP: PhaseBio Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Short Bowel Syndrome Key Companies
- Short Bowel Syndrome Key Products
- Short Bowel Syndrome- Unmet Needs
- Short Bowel Syndrome- Market Drivers and Barriers
- Short Bowel Syndrome- Future Perspectives and Conclusion
- Short Bowel Syndrome Analyst Views
- Short Bowel Syndrome Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.